drugset / Trial / NCT02935725

A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males

NCT02935725

RandomizedCrossoverTriple-blindTreatment

Summary

A Phase 1, Single-centre, Double-blind, Placebo controlled Crossover Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Male Participants

Timeline

Start
2016-10
Primary completion
2017-11
Completion
2017-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AUT00206 Small molecule 800 mg
Subject AUT00206 Small molecule 2000 mg
Background Ketamine Small molecule

Indications